Memry

Memry Drug Interactions

memantine

Manufacturer:

Medichem

Distributor:

United Lab
Full Prescribing Info
Drug Interactions
N-methyl-D-aspartate antagonists (amantadine, ketamine and dextromethorphan): Increased risk of CNS toxicity when memantine hydrochloride is given with NMDA antagonists. Avoid concomitant use. These compounds act at the same receptor system as memantine hydrochloride, and thus adverse drug reactions, mainly CNS-related, may be more frequent or more pronounced.
L-dopa, dopaminergic agonists (e.g., bromocriptine) and anticholinergics: The mode of action suggests that the effects of these drugs may be enhanced by concomitant treatment with NMDA-antagonists such as memantine hydrochloride.
Barbiturates and neuroleptics: The effects of these drugs may be reduced by memantine hydrochloride.
Antispasmodic agents (dantrolene or baclofen): Concomitant administration of memantine hydrochloride with the antispasmodic agents, dantrolene or baclofen, can modify their effects and a dosage adjustment may be necessary.
Oral anticoagulants (e.g., warfarin): Memantine hydrochloride possibly enhances the anticoagulant effect of warfarin. Close monitoring of prothrombin time or INR is advisable for patients concomitantly treated with oral anticoagulants.
Cimetidine, ranitidine, procainamide, quinidine, quinine, and nicotine: May also possibly interact with memantine hydrochloride leading to a potential risk of increased plasma levels of both agents.
Diuretics [e.g., hydrochlorothiazide (HCTZ), triamterene (TA)]: There may be a possibility of reduced HCTZ plasma level when memantine hydrochloride is used concomitantly. However, co-administration of memantine hydrochloride and HCTZ/TA did not affect the bioavailability of either memantine hydrochloride or TA; the bioavailability of HCTZ is decreased by 20%.
Primidone: Memantine hydrochloride possibly reduces the effects of primidone.
Selegiline: Memantine hydrochloride possibly enhances the effects of selegiline.
Glibenclamide/metformin, donepezil and galantamine: No relevant drug-drug interaction.
Effects of memantine on substrates of microsomal enzymes: In vitro studies done with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine hydrochloride. Also, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine hydrochloride does not induce the cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2E1, and CYP3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in